Our Sarah Cannon locations bring together physician leadership, cutting-edge technology and specialized nurse navigation to support our patients throughout their cancer journey. Our approach includes:

• A multi-disciplinary approach that aligns board-certified and highly-experienced surgical, medical, and radiation oncologists to lead the development of care pathways and collaborate on personalized care plans through tumor boards.
• Use of the latest technology for imaging and profiling to ensure that staging and tumor characterization are developed with precision, beginning at diagnosis, so that the best care plan can be recommended for the patient.
• Data informatics systems that are customized to measure quality and constantly improve processes from the point of diagnosis through survivorship.
• A Nurse Navigation program that ensures patients and their team of physicians can have a constant point of contact through the cancer journey. Sarah Cannon Nurse Navigators are required to have special training in specific cancer types to help the patient in understanding their unique cancer, assist in removing barriers, and offer emotional support for the patient and their family.

Sarah Cannon was a television and radio personality, known worldwide for her Grand Ole Opry character “Minnie Pearl.” After receiving treatment for breast cancer at our founding center in Nashville, she offered the use of her given name to promote cancer research and patient education with a vision of offering patients convenient access to early detection, clinical trials and a team approach to cancer care.

Sarah Cannon Cancer Network has been leading the fight against cancer since 1993, when a team of physicians came together with a shared vision: to make cancer clinical trials accessible to the community. With a focus on offering patients greater access to clinical trials in the earliest phases of their cancer journey, our founders established the Sarah Cannon Cancer Center in Nashville, Tennessee – the first community-based cancer research program. Four years later, they created the first drug development program outside of an academic setting, further proving their dedication and innovative approach. This program is now one of the largest of its kind in the world.

In 2004, our offerings expanded into communities across the United States and United Kingdom when we formed the Sarah Cannon Research Institute (SCRI), one of the largest patient-centric clinical trial organizations in the world conducting drug development at every phase, including first-in-human studies.

Sarah Cannon became the Cancer Institute of HCA Healthcare in 2012. Extending our reach far beyond clinical trials for cancer and with the ability to impact more communities, we are committed to addressing every aspect of care – from diagnosis through recovery.

In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 24 states. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development.

To meet the evolving needs of communities, HCA Healthcare embarked on a journey to redefine its cancer care offering to physicians and patients. In 2024, the Sarah Cannon Cancer Network was brought to life. Today, the network comprises partnering hospitals offering world-class cancer care close to home for hundreds of thousands of patients, unmatched by any cancer center.